Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03579459 · ClinicalTrials.gov registry record · Phase 3
Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age
A Phase 3 study of Clostridium Difficile Associated Disease, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,317
- Enrollment target
- 20
- Study locations
NCT03579459 is a Phase 3 study of Clostridium Difficile Associated Disease that has completed, run by Pfizer. The registered enrollment target is 1,317 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT03579459, a Phase 3 study of Clostridium Difficile Associated Disease, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,317 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will investigate a Clostridium difficile vaccine in healthy adults 65 to 85 years of age, who will each receive 3 doses of vaccine. The study will assess the lot consistency, safety, and tolerability of the vaccine, and also look at the subjects' immune response to the vaccine.
Conditions Studied
Interventions
- BIOLOGICAL placebo
- BIOLOGICAL Clostridium difficile vaccine
Study Locations (20)
Florida
- Clinical Research of South Florida - Coral Gables
- Avail Clinical Research, LLC - DeLand
- Research Centers of America, LLC - Hollywood
Georgia
- Atlanta Center for Medical Research - Atlanta
- Clinical Research Atlanta - Stockbridge
Nebraska
- Meridian Clinical Research, LLC - Norfolk
- Meridian Clinical Research, LLC - Omaha
North Carolina
- PMG Research of Charlotte, LLC - Charlotte
- PMG Research of Wilmington, LLC - Wilmington
Texas
- Benchmark Research - Austin
- Diagnostics Research Group - San Antonio
Alabama
- Coastal Clinical Research, Inc. - Mobile
California
- Paradigm Clinical Research Centers, Inc. - Redding
Hawaii
- East-West Medical Research Institute - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,317 participants |
| Start Date | 2018-07-31 |
| Est. Completion | 2019-08-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03579459
The ClinicalTrials.gov registry entry for NCT03579459 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Clostridium Difficile Associated Disease appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT03579459 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Georgia, Nebraska.
Frequently Asked Questions
What is clinical trial NCT03579459 about?
NCT03579459 is a clinical study titled "Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age". This study will investigate a Clostridium difficile vaccine in healthy adults 65 to 85 years of age, who will each receive 3 doses of vaccine. The study will assess the lot consistency, safety, and tolerability of the vaccine, and also look at the subjects' immune response to the vaccine.
What is the current status of trial NCT03579459?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,317 participants. The study started on 2018-07-31. Estimated completion is 2019-08-06.
What conditions does trial NCT03579459 study?
This clinical trial studies the following conditions: Clostridium Difficile Associated Disease.
What interventions are being tested in trial NCT03579459?
The interventions under investigation include: placebo (BIOLOGICAL), Clostridium difficile vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03579459?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03579459 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridium Difficile Associated Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
COMPLETED · Phase 2
-
Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.